TY - JOUR
T1 - E2F7 Is a Potent Inhibitor of Liver Tumor Growth in Adult Mice
AU - Moreno, Eva
AU - Toussaint, Mathilda J.M.
AU - van Essen, Saskia C.
AU - Bongiovanni, Laura
AU - van Liere, Elsbeth A.
AU - Koster, Mirjam H.
AU - Yuan, Ruixue
AU - van Deursen, Jan M.
AU - Westendorp, Bart
AU - de Bruin, Alain
N1 - Funding Information:
We thank Wout Puijk and the rest of the animal caretakers for excellent care of our mice during experiments. Ger Arkesteijn (Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands) and Reinier van der Linden (Hubrecht Institute, Utrecht, the Netherlands) for providing professional assistance with FACS. We also thank Rosan Heijboer for generation of the RPE inducible cell lines and Rachel Thomas for her contribution to the manuscript revision.
Publisher Copyright:
© 2020 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
PY - 2021/1
Y1 - 2021/1
N2 - Background and Aims: Up-regulation of the E2F-dependent transcriptional network has been identified in nearly every human malignancy and is an important driver of tumorigenesis. Two members of the E2F family, E2F7 and E2F8, are potent repressors of E2F-dependent transcription. They are atypical in that they do not bind to dimerization partner proteins and are not controlled by retinoblastoma protein. The physiological relevance of E2F7 and E2F8 remains incompletely understood, largely because tools to manipulate their activity in vivo have been lacking. Approach and Results: Here, we generated transgenic mice with doxycycline-controlled transcriptional activation of E2f7 and E2f8 and induced their expression during postnatal development, in adulthood, and in the context of cancer. Systemic induction of E2f7 and, to lesser extent, E2f8 transgenes in juvenile mice impaired cell proliferation, caused replication stress, DNA damage, and apoptosis, and inhibited animal growth. In adult mice, however, E2F7 and E2F8 induction was well tolerated, yet profoundly interfered with DNA replication, DNA integrity, and cell proliferation in diethylnitrosamine-induced liver tumors. Conclusion: Collectively, our findings demonstrate that atypical E2Fs can override cell-cycle entry and progression governed by other E2F family members and suggest that this property can be exploited to inhibit proliferation of neoplastic hepatocytes when growth and development have subsided during adulthood.
AB - Background and Aims: Up-regulation of the E2F-dependent transcriptional network has been identified in nearly every human malignancy and is an important driver of tumorigenesis. Two members of the E2F family, E2F7 and E2F8, are potent repressors of E2F-dependent transcription. They are atypical in that they do not bind to dimerization partner proteins and are not controlled by retinoblastoma protein. The physiological relevance of E2F7 and E2F8 remains incompletely understood, largely because tools to manipulate their activity in vivo have been lacking. Approach and Results: Here, we generated transgenic mice with doxycycline-controlled transcriptional activation of E2f7 and E2f8 and induced their expression during postnatal development, in adulthood, and in the context of cancer. Systemic induction of E2f7 and, to lesser extent, E2f8 transgenes in juvenile mice impaired cell proliferation, caused replication stress, DNA damage, and apoptosis, and inhibited animal growth. In adult mice, however, E2F7 and E2F8 induction was well tolerated, yet profoundly interfered with DNA replication, DNA integrity, and cell proliferation in diethylnitrosamine-induced liver tumors. Conclusion: Collectively, our findings demonstrate that atypical E2Fs can override cell-cycle entry and progression governed by other E2F family members and suggest that this property can be exploited to inhibit proliferation of neoplastic hepatocytes when growth and development have subsided during adulthood.
UR - http://www.scopus.com/inward/record.url?scp=85100572879&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100572879&partnerID=8YFLogxK
U2 - 10.1002/hep.31259
DO - 10.1002/hep.31259
M3 - Article
C2 - 32259305
AN - SCOPUS:85100572879
SN - 0270-9139
VL - 73
SP - 303
EP - 317
JO - Hepatology
JF - Hepatology
IS - 1
ER -